Loading...
Loading...
BIIB| Name | Value |
|---|---|
| Revenues | 2,386.3M |
| Cost of Revenue | 618.3M |
| Gross Profit | 1,768.0M |
| Operating Expense | 1,310.3M |
| Operating I/L | 291.6M |
| Other Income/Expense | -133.6M |
| Interest Income | 23.8M |
| Pretax | 291.6M |
| Income Tax Expense | 42.7M |
| Net Income/Loss | 249.7M |
Biogen Inc. is a biotechnology company specializing in the discovery, development, and commercialization of therapies for neurological and neurodegenerative diseases. The company's product portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, plaque psoriasis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, vasculitis, pemphigus vulgaris, and other neurological and immunological disorders. Biogen also develops biosimilars and has collaboration and license agreements with various pharmaceutical companies. The company generates revenue through the sale of its proprietary therapies and through partnerships and licensing agreements.
